HumeCare Oral GLP-1 

Clinical Efficacy: Oral GLP-1 Data

 

Get HumeCare Oral GLP-1 Today!

Get Started Today — Shop HumeCare Now!

HumeCare's program is grounded in an expanding body of clinical trial and real-world evidence demonstrating the efficacy of oral GLP-1 formulations across diverse patient populations.

Novo Nordisk — OASIS 4 Trial

16.6% average weight loss at oral semaglutide 25 mg vs. 2.7% placebo. 34.4% of patients achieved ≥20% body weight reduction. Secondary endpoints included improved physical function across everyday activities (bending, standing, walking, sustained physical activity) and measurable improvements in cardiovascular risk factors — extending the clinical value proposition beyond weight alone.